Chemical Probes Based on IL-18 Reveal Shared Caspase Specificities

Study Background and Research Question

Caspases, a family of cysteine proteases, orchestrate both inflammation and programmed cell death (apoptosis and pyroptosis). Distinctions between inflammatory caspases (e.g., caspase-1, -4, -5, -11) and apoptotic initiator caspases (e.g., caspase-8, -9) are functionally and mechanistically critical in immunology and cell death research. However, overlapping substrate preferences and the lack of highly selective chemical tools have complicated the precise dissection of caspase functions, especially when studying cytokine processing and cell death modalities in macrophages and other immune cells. The reference study addresses these challenges by investigating whether substrate and inhibitor specificities can be rationally dissected using peptide motifs derived from natural cytokine processing sites (paper).

Key Innovation from the Reference Study

The central innovation is the design and application of new chemical tools—specifically a substrate probe and a peptide-based inhibitor—based on the LESD tetrapeptide cleavage site of interleukin-18 (IL-18). This approach provides a direct and physiologically relevant means to probe the substrate and inhibitor selectivity of both inflammatory and apoptotic caspases. Notably, the LESD-based inhibitor exhibits unexpected potency and selectivity toward caspase-8, exceeding that of the commonly used z-IETD-FMK inhibitor, and also enables detailed comparative profiling of substrate and inhibitor preferences across multiple caspases (paper).

Methods and Experimental Design Insights

The study employs a combination of recombinant caspase activity assays and infection models in primary bone marrow-derived macrophages. The key methodological advance is the use of a synthetic peptide substrate and corresponding inhibitor, tailored from the IL-18 processing motif (LESD), to evaluate cleavage and inhibition kinetics across a panel of caspases—specifically caspases-1, -4, -5 (inflammatory) and caspases-8, -9 (apoptotic initiators). Inhibitor potency is measured via IC₅₀ values under standardized activity units for each caspase, ensuring direct quantitative comparison. The impact of these inhibitors is also tested in macrophages infected with Yersinia pseudotuberculosis, a context where both caspase-1 and caspase-8 can be activated.

Protocol Parameters

• caspase-8 inhibition assay | IC₅₀ = 50 nM (LESD-based inhibitor) | in vitro profiling | identifies highly potent and selective inhibition over traditional z-IETD-FMK | paper
• caspase-8 inhibition assay | IC₅₀ = 1 μM (VX-765) | in vitro profiling | reveals cross-inhibition by a nominally caspase-1 selective inhibitor | paper
• macrophage infection model | primary bone marrow-derived macrophages, Y. pseudotuberculosis infection | physiological relevance | demonstrates inhibitor effects in a disease model | paper
• workflow suggestion: recombinant caspase activity assays | 10-100 nM enzyme, 1-100 μM inhibitor | in vitro selectivity profiling | recommended for initial screening of caspase inhibitors | workflow_recommendation
• workflow suggestion: cell-based pyroptosis inhibition | 1-10 μM inhibitor dosing | macrophage models | to assess functional impact on cell death and cytokine release | workflow_recommendation

Core Findings and Why They Matter

The study's comparative profiling demonstrates that inflammatory and apoptotic initiator caspases can share overlapping substrate and inhibitor specificities, contrary to longstanding assumptions of strict selectivity. The LESD-based inhibitor potently blocks caspase-8 (IC₅₀ = 50 nM), outperforming z-IETD-FMK (the previous standard for caspase-8 inhibition). Importantly, VX-765—the widely used selective caspase-1 inhibitor—also inhibits caspase-8, albeit with lower potency (IC₅₀ = 1 μM), indicating that conclusions drawn from experiments using VX-765 may be confounded by off-target effects on apoptotic caspases (paper).

These results have substantial implications for studies of inflammation and pyroptosis, especially in contexts where both caspase-1 and caspase-8 may be co-activated (such as during certain bacterial infections or in engineered cell death models). The finding that VX-765 can influence not only inhibition of IL-1β and IL-18 release but also processes related to apoptosis via caspase-8 prompts careful interpretation of experimental data and suggests a need for even more selective chemical tools in dissecting caspase biology.

Comparison with Existing Internal Articles

Recent internal resources have highlighted VX-765 as a powerful and selective caspase-1 inhibitor, enabling precise study of cytokine processing, pyroptosis inhibition in macrophages, and disease modeling in contexts such as rheumatoid arthritis and HIV-associated CD4 T-cell pyroptosis (internal article 1; internal article 2). These articles emphasize VX-765’s selectivity for caspase-1 and its robust effects on inhibition of IL-1β and IL-18 release, supporting its widespread use in inflammation research and in vivo models. However, the present study nuances this perspective by demonstrating that VX-765 also inhibits caspase-8, though less potently, potentially impacting experimental outcomes where both inflammatory and apoptotic pathways are active. This cross-inhibition was not previously accounted for in standard workflow recommendations, underscoring the value of the new peptide-based probes for more precise pathway dissection.

Limitations and Transferability

While the LESD-based inhibitor provides new selectivity for caspase-8, and VX-765’s profile is further clarified, the study is limited by its in vitro and ex vivo focus. The exact in vivo relevance of cross-caspase inhibition—especially at physiological concentrations—requires further exploration. Additionally, the study’s findings are most directly transferable to macrophage and inflammasome research, with broader relevance to any setting where inflammatory and apoptotic caspases may be co-activated. However, as with all chemical probes, conclusions about pathway selectivity must be contextualized with respect to inhibitor concentration, cell type, and upstream stimuli.

Why this cross-domain matters, maturity, and limitations

The cross-inhibition of caspase-8 by VX-765 highlights the interconnectedness of inflammatory and apoptotic pathways in immune cells. This is particularly relevant in infectious disease settings, where both forms of programmed cell death may be triggered simultaneously. However, these insights are primarily supported by in vitro and ex vivo data; translation to in vivo models will require careful dose-response validation and may be influenced by the metabolic conversion of VX-765 to VRT-043198 (paper).

Research Support Resources

For researchers aiming to dissect caspase-1–mediated processes or to explore the intersection of inflammatory and apoptotic caspase activity, the use of well-characterized, selective inhibitors remains essential. VX-765, Caspase-1 inhibitor, potent and selective (SKU A8238) is widely used for the inhibition of IL-1β and IL-18 release and for studying pyroptosis in macrophages. Its in vivo metabolite, VRT-043198, offers reliable caspase-1 targeting, though the current study underscores the importance of considering potential off-target effects on caspase-8 in workflows where both inflammatory and apoptotic pathways are relevant (paper; internal article 1). Researchers are advised to carefully match inhibitor selection and assay design to their experimental questions, leveraging new findings on inhibitor selectivity for more robust mechanistic conclusions.